Competition Shifts to Delivery and Safety

The bottleneck in cellular rejuvenation is no longer proving that cells can look younger in a lab, it is turning that biology into a drug that can be delivered safely, made consistently, and tested first in a disease where improvement is measurable. That is why the leaders are now separating by vector choice, dose control, organ target, and clinical execution, not by famous scientists or paper count.

• Life Biosciences has already crossed into humans with ER-100, an AAV gene therapy for optic neuropathies. FDA clearance came on January 28, 2026, and the first patient was dosed on June 9, 2026. That gives Life the first real read on immune response, tolerability, and whether any biomarker moves in patients.
  1 lifebiosciences 4 globenewswire
• NewLimit is competing on a different axis, narrower scope and faster engineering. It raised $435M in June 2026, is using AI guided screening with an initial liver focus, and plans human trials in 2027. Its emphasis on RNA and transient expression matters because redosing and dose control are practical advantages over one time AAV delivery.
  2 newlimit 5 fiercebiotech
• Altos and Calico look most alike organizationally, but Calico already has active clinical programs, including a Phase 2 study in ADPKD. That shows the current edge goes to groups that can connect aging biology to a specific indication, manufacturing plan, and trial design, even without owning the broadest rejuvenation platform.
  3 sacra 6 calicolabs 7 calicolabs

The next phase of the market will be won by companies that can show a repeatable path from cell state change to approved medicine. The decisive milestones will be first human safety data, cleaner delivery systems, and initial diseases where regulators and doctors can see a clear benefit, then reuse that playbook across more organs and modalities.